Oculis Holding AG OCS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Oculis Holding AG is a biopharmaceutical company focused on developing innovative ophthalmic treatments to preserve vision and improve eye care. The company concentrates on diseases with significant unmet medical needs, particularly in retinal and neuro-ophthalmology indications. Its current pipeline includes OCS-01, a…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountrySwitzerland
Employees60
TickerOCS
Statistics
Market Cap$682.4M
Revenue (TTM)$1.1M
Net Income—
Net Margin—
EPS—
P/E63.63
P/S602.00
P/B2.71
EV/EBITDA-5.33
ROE-52.7%
Dividend Yield—
Price$11.30
Data: Twelve Data · Revenue = mcap / P/S